GLP1 Agonists: Indeed, numerous studies have demonstrated the potential benefits of GLP-1 receptor agonists in NAFLD, particularly in those with diabetes. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.